Replies to post #94302 on Elite Pharmaceuticals Inc (ELTP)

[Couch]

*****NOTE: Read the quote at the bottom FIRST.
Wrap your mind around the fact that Elite is still doing studies not Phase II or III trials! Get in while you can under a buck.

I bought my first shares in March of 2011 when the stock was at .07 cents. The company had no ART patents and I had never heard of Nasrat Hakim let alone Alpharma where he originally worked and from where Pfizer's ADT patents come from in essence.

I stood 50% underwater many more nights/months than I care to remember but kept buying hand over fist. My .06 cent shares have over 1200% ROI and I've not put one single ELTP dollar in my pocket since day one. My RoI is all on paper. Tenacious or delusional. Many of those here might actually consider me both Cooler and I daresay I should probably have written would. I'd say I'm one of the sanest men on the planet when it comes to being a value investor and picking undervalued companies though I have more help than my mind often feels comfortable with. I call them the crew. Key Word: Investor!

Whether it climbs post a buck on partnership news by the end of the month or dips to that hoped for .50 or dare I say lower ~ I know what I have and the climb above the unlimited shares below .20 I was promised prior to March~ Lmao by the way on that call.... only proves what I knew back in 2011 and still believe today. Elite is highly undervalued given the patented abuse resistant technology it owns. Intellectual patent rights to the multi billion dollar opioid space. It's why I'm here! To build a better painkiller. Here's but a small reminder of what I believe. The date was June 11, 2013 when the PPS LOD was .067 and the volume a dismal 339,853 share traded in total. I bought 40K shares that day for less than $3K.

Elite Pharmaceuticals (ELTP)--Intellectual Property (IP) And The Right To Devise A Better Pain Killer!
http://seekingalpha.com/user/4199131/instablog

This staggering possibility is better understood when you realize that shares bought now before trials begin have the real potential to set one up for a really nice financial windfall within the next few years. After all, Elite has technology that is going to give Purdue and Pfizer a run for their money in the abuse deterrent/resistant opioid space.